A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy

Niranjan Manoharan, Prem Sagar Subramanian

Research output: Contribution to journalArticle

Abstract

Purpose To report the first reported case of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of Harvoni (Gilead Sciences, Foster City, CA, USA), a newly approved treatment for Hepatitis C. Observations We report a case of NAION in a hepatitis C patient who completed Harvoni therapy just prior to presentation. Harvoni was suspected to be the causative agent given a lack of NAION risk factors in an otherwise healthy young patient. Conclusions NAION is an acute, painless vision loss that typically affects adults over 50. The mechanism of NAION remains uncertain although numerous associations have been identified including certain medications. Harvoni, a combination drug of ledipasvir/sofosbuvir, is a recently FDA-approved treatment for Hepatitis C. To date, however, no ophthalmological side effects have been reported with its use. Continued surveillance of patients treated with Harvoni will be needed to determine if additional events are observed in the future.

Original languageEnglish (US)
Pages (from-to)55-57
Number of pages3
JournalAmerican Journal of Ophthalmology Case Reports
Volume6
DOIs
StatePublished - Jun 1 2017
Externally publishedYes

Fingerprint

Ischemic Optic Neuropathy
Hepatitis C
Therapeutics
sofosbuvir drug combination ledipasvir

Keywords

  • Harvoni
  • Ischemic optic neuropathy
  • NAION

ASJC Scopus subject areas

  • Ophthalmology

Cite this

A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy. / Manoharan, Niranjan; Subramanian, Prem Sagar.

In: American Journal of Ophthalmology Case Reports, Vol. 6, 01.06.2017, p. 55-57.

Research output: Contribution to journalArticle

@article{b06c11975f57446baca36908aacfe8ed,
title = "A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy",
abstract = "Purpose To report the first reported case of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of Harvoni (Gilead Sciences, Foster City, CA, USA), a newly approved treatment for Hepatitis C. Observations We report a case of NAION in a hepatitis C patient who completed Harvoni therapy just prior to presentation. Harvoni was suspected to be the causative agent given a lack of NAION risk factors in an otherwise healthy young patient. Conclusions NAION is an acute, painless vision loss that typically affects adults over 50. The mechanism of NAION remains uncertain although numerous associations have been identified including certain medications. Harvoni, a combination drug of ledipasvir/sofosbuvir, is a recently FDA-approved treatment for Hepatitis C. To date, however, no ophthalmological side effects have been reported with its use. Continued surveillance of patients treated with Harvoni will be needed to determine if additional events are observed in the future.",
keywords = "Harvoni, Ischemic optic neuropathy, NAION",
author = "Niranjan Manoharan and Subramanian, {Prem Sagar}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.ajoc.2017.03.002",
language = "English (US)",
volume = "6",
pages = "55--57",
journal = "American Journal of Ophthalmology Case Reports",
issn = "2451-9936",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - A case of non-arteritic anterior ischemic optic neuropathy after completion of Harvoni therapy

AU - Manoharan, Niranjan

AU - Subramanian, Prem Sagar

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Purpose To report the first reported case of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of Harvoni (Gilead Sciences, Foster City, CA, USA), a newly approved treatment for Hepatitis C. Observations We report a case of NAION in a hepatitis C patient who completed Harvoni therapy just prior to presentation. Harvoni was suspected to be the causative agent given a lack of NAION risk factors in an otherwise healthy young patient. Conclusions NAION is an acute, painless vision loss that typically affects adults over 50. The mechanism of NAION remains uncertain although numerous associations have been identified including certain medications. Harvoni, a combination drug of ledipasvir/sofosbuvir, is a recently FDA-approved treatment for Hepatitis C. To date, however, no ophthalmological side effects have been reported with its use. Continued surveillance of patients treated with Harvoni will be needed to determine if additional events are observed in the future.

AB - Purpose To report the first reported case of non-arteritic anterior ischemic optic neuropathy (NAION) associated with the use of Harvoni (Gilead Sciences, Foster City, CA, USA), a newly approved treatment for Hepatitis C. Observations We report a case of NAION in a hepatitis C patient who completed Harvoni therapy just prior to presentation. Harvoni was suspected to be the causative agent given a lack of NAION risk factors in an otherwise healthy young patient. Conclusions NAION is an acute, painless vision loss that typically affects adults over 50. The mechanism of NAION remains uncertain although numerous associations have been identified including certain medications. Harvoni, a combination drug of ledipasvir/sofosbuvir, is a recently FDA-approved treatment for Hepatitis C. To date, however, no ophthalmological side effects have been reported with its use. Continued surveillance of patients treated with Harvoni will be needed to determine if additional events are observed in the future.

KW - Harvoni

KW - Ischemic optic neuropathy

KW - NAION

UR - http://www.scopus.com/inward/record.url?scp=85020750085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020750085&partnerID=8YFLogxK

U2 - 10.1016/j.ajoc.2017.03.002

DO - 10.1016/j.ajoc.2017.03.002

M3 - Article

C2 - 29260058

AN - SCOPUS:85020750085

VL - 6

SP - 55

EP - 57

JO - American Journal of Ophthalmology Case Reports

JF - American Journal of Ophthalmology Case Reports

SN - 2451-9936

ER -